Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Update

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a large drop in short interest during the month of July. As of July 15th, there was short interest totalling 448,000 shares, a drop of 52.7% from the June 30th total of 947,400 shares. Based on an average daily volume of 4,950,000 shares, the days-to-cover ratio is currently 0.1 days.

Sonoma Pharmaceuticals Stock Down 7.3 %

NASDAQ SNOA traded down $0.03 during trading on Friday, hitting $0.35. The stock had a trading volume of 719,831 shares, compared to its average volume of 4,188,936. The company has a market capitalization of $6.67 million, a PE ratio of -0.48 and a beta of 1.38. The firm has a 50 day moving average price of $0.25 and a 200 day moving average price of $0.19. Sonoma Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $1.15.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its quarterly earnings data on Monday, June 17th. The company reported ($0.07) EPS for the quarter. Sonoma Pharmaceuticals had a negative return on equity of 64.15% and a negative net margin of 37.97%. The company had revenue of $3.44 million for the quarter. On average, sell-side analysts anticipate that Sonoma Pharmaceuticals will post -0.2 earnings per share for the current year.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.